BioNTech (NASDAQ:BNTX) Releases Quarterly Earnings Results, Misses Estimates By $0.89 EPS

BioNTech (NASDAQ:BNTX) released its earnings results on Monday. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of $0.75 by ($0.89), Zacks reports. The firm had revenue of $1.78 billion during the quarter, compared to analysts’ expectations of $1.21 billion. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The firm’s revenue was up 22.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.81 earnings per share. BioNTech updated its FY 2025 guidance to EPS.

BioNTech Stock Performance

NASDAQ:BNTX opened at $103.96 on Tuesday. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $23.41 billion, a price-to-earnings ratio of -64.97 and a beta of 1.45. The firm’s fifty day simple moving average is $102.50 and its 200 day simple moving average is $105.01. BioNTech has a twelve month low of $81.20 and a twelve month high of $129.27.

Analysts Set New Price Targets

Several research firms have commented on BNTX. Bank of America lowered their target price on shares of BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a research note on Wednesday, October 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a research note on Tuesday, October 14th. Morgan Stanley reissued an “overweight” rating and set a $134.00 price objective on shares of BioNTech in a research note on Monday. JPMorgan Chase & Co. lowered their price objective on shares of BioNTech from $121.00 to $120.00 and set a “neutral” rating for the company in a research note on Thursday, October 23rd. Finally, HC Wainwright reissued a “buy” rating and set a $136.00 price objective on shares of BioNTech in a research note on Monday, September 8th. Ten analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and a consensus price target of $134.17.

Institutional Investors Weigh In On BioNTech

Several hedge funds and other institutional investors have recently bought and sold shares of BNTX. Tower Research Capital LLC TRC boosted its stake in shares of BioNTech by 118.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after buying an additional 305 shares during the last quarter. NewEdge Advisors LLC acquired a new stake in BioNTech in the first quarter valued at $167,000. Osaic Holdings Inc. boosted its stake in BioNTech by 27.3% during the 2nd quarter. Osaic Holdings Inc. now owns 1,949 shares of the company’s stock valued at $208,000 after acquiring an additional 418 shares during the last quarter. Boothbay Fund Management LLC bought a new position in BioNTech during the 2nd quarter valued at $319,000. Finally, Royal Bank of Canada boosted its stake in BioNTech by 95.9% during the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after acquiring an additional 3,514 shares during the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.